NCT03164044

Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy

Improved Basophil Activation Test (BAT) in the Diagnostics of IgE-mediated Drug Allergy

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 45 (actual)
• Sponsor: The Republican Research and Practical Center for Epidemiology and Microbiology · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs).

Detailed description

Current study evaluates the use of the improved Basophil Activation Test (BAT) in the diagnostics of IgE-mediated allergy to antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs). Among commonly used CD63/CD203c markers, newly proposed molecules, such as CD69, CD107a, CD164, CD13, CD11b and CD300a will be assayed. Results obtained together with the other clinical data will be used to calculate sensitivity and specificity of the method.

Conditions

• Drug Allergy
• Antibiotic Allergy
• NSAID-Induced Anaphylactoid Reaction

Timeline

• Start date: 2017-01-03
• Primary completion: 2018-12-11
• Completion: 2019-06-30
• First posted: 2017-05-23
• Last updated: 2018-12-17

Locations

1 site across 1 country: Belarus